Drug Trial Radar · NCT00299000
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Last checked: Nov 20, 2026Latest source record: Jul 22, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4
Actual
Start
May 2006
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Mar 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, up to 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.
Conditions
- Mucopolysaccharidosis VI
- Maroteaux-Lamy Syndrome
Interventions
NaglazymeDrug
Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HeightTime frame: 52 weeks
- Change in WeightTime frame: 52 weeks
- Change in Haed CircumferenceTime frame: 52 weeks
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
Children's Hospital Oakland
Oakland, California
Hospital Femme Mere Enfant Centre
Lyon, France
Hospital PediAtrico de Coimbra
Coimbra, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.